Stocks Health care BDTX
NASDAQ · Health careBlack Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. brought in $0 of revenue over the twelve months to June 30, 2026, down 100.0% from a year earlier. It posted a net loss of $42.6M. At June 30, 2026 it held $19.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Black Diamond Therapeutics, Inc. does
Black Diamond Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BDTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $70M | $22.4M | $0.39 | n/a |
| 2024 | $0 | -$69.7M | -$1.27 | -$62.3M |
| 2023 | n/a | -$82.4M | -$1.88 | -$66.8M |
| 2022 | n/a | -$91.2M | -$2.52 | -$85.3M |
| 2021 | n/a | -$125.6M | -$3.47 | -$102.9M |
| 2020 | $0 | -$67.3M | -$2.05 | -$52.3M |
Latest SEC filings
What Black Diamond Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- June 29, 2026
- May 21, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026
- May 7, 2026
- April 29, 2026
- April 29, 2026Additional proxy material DEFA14A
Questions about BDTX
What does Black Diamond Therapeutics, Inc. do?
Black Diamond Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker BDTX.
Is Black Diamond Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $42.6M.
How much revenue does Black Diamond Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Black Diamond Therapeutics, Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Black Diamond Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 21, 2026.
Similar companies
Follow BDTX
Get an email when Black Diamond Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BDTX: get an email when it filesWhere the numbers come from
Financial figures are the values Black Diamond Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.